× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Findings

What does this study add?

  • Compared to baseline (42%), glucose time >180 mg/dL during daytime decreased to 37% and 34% with 670G and AHCL, respectively.
  • Glucose profiles were consistently lower with AHCL vs. 670G.
  • TIR (time in range)70-180 was 63% with 670G and 67% with AHCL compared to 57% at baseline; time >180 mg/dL was 34% with 670G and 31% with AHCL vs. 41% at baseline.
  • Changes in TIR were seen across all age groups, baseline HbA1c, and previous use of technology.
  • Compared to a baseline of 7.9%, HbA1c decreased to 7.6% and 7.4% with 670G and AHCL, respectively.
  • Patient reported satisfaction significantly favored AHCL over 670G.
  • Safety analyses have shown 6 events for 670G (3 hyperglycemia or ketosis related to insulin pump problem; 1 hyperglycemia or ketosis not related to insulin pump problem; 2 other serious adverse events), and 3 for AHCL (1 severe hypoglycemia; 2 hyperglycemia or ketosis related to insulin pump problem).